


ENTERING A NEW ERA IN METABOLIC DYSFUNCTION- ASSOCIATED STEATOHEPATITIS:

Examining the
Clinical Implications
of Emerging Disease-
Specific Therapies



Suggested Readings

The Growing Burden of MASLD/MASH: A Call to Action

Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. *Gastroenterology*. 2015;149:389-397. doi:10.1053/j.gastro.2015.04.043

Banach M, Lewek J, Surma S, et al. The association between daily step count and all-cause and cardiovascular mortality: a meta-analysis. *Eur J Prev Cardiol*. 2023;30:1975-1985. doi:10.1093/eurjpc/zwad229

Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). *Endocr Pract*. 2022;28:528-562. doi:10.1016/j.eprac.2022.03.010

Harrison SA, Gawrieh S, Roberts K, et al. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. *J Hepatol*. 2021;75:284-291. doi:10.1016/j.jhep.2021.02.034

Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040. *Diabetes Res Clin Pract*. 2017;128:40-50. doi:10.1016/j.diabres.2017.03.024

Stierman B, Afful J, Carroll MD, et al. National Health and Nutrition Examination Survey 2017–March 2020 prepandemic data files—development of files and prevalence estimates for selected health outcomes. *National Health Statistics Reports*. No. 158. National Center for Health Statistics. 2021.

<https://www.cdc.gov/nchs/data/nhsr/nhsr158-508.pdf>

Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. *Gastroenterology*. 2015;149:367-378.e5. doi:10.1053/j.gastro.2015.04.005

Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. *Gastroenterology*. 2011;140:124-131. doi:10.1053/j.gastro.2010.09.038

Wong RJ, Singal AK. Trends in liver disease etiology among adults awaiting liver transplantation in the United States, 2014-2019. *JAMA Netw Open*. 2020;3:e1920294. doi:10.1001/jamanetworkopen.2019.20294

Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. *Hepatology*. 2023;77:1335-1347. doi:10.1097/HEP.0000000000000004

THR- β Agonists and Other Disease-Specific Therapies Poised to Change the Paradigm

Bano A, Chaker L, Plompen EPC, et al. Thyroid function and the risk of nonalcoholic fatty liver disease: The Rotterdam Study. *J Clin Endocrinol Metab*. 2016;101:3204-3211. doi:10.1210/jc.2016-1300

Bohinc BN, Michelotti G, Xie G, et al. Repair-related activation of hedgehog signaling in stromal cells promotes intrahepatic hypothyroidism. *Endocrinology*. 2014;155:4591-4601. doi:10.1210/en.2014-1302

Brandt SJ, Kleinert M, Tschöp MH, et al. Are peptide conjugates the golden therapy against obesity? *J Endocrinol*. 2018;238:R109-R119. doi:10.1530/JOE-18-0264

Bruinstroop E, Dalan R, Cao Y, et al. Low-dose levothyroxine reduces intrahepatic lipid content in patients with type 2 diabetes mellitus and NAFLD. *J Clin Endocrinol Metab*. 2018;103:2698-2706. doi:10.1210/jc.2018-00475

Bruinstroop E, Zhou J, Tripathi M, et al. Early induction of hepatic deiodinase type 1 inhibits hepatosteatosis during NAFLD progression. *Mol Metab*. 2021;53:101266. doi:10.1016/j.molmet.2021.101266

Chen Z, Yang L, Liu Y, et al. The potential function and clinical application of FGF21 in metabolic diseases. *Front Pharmacol*. 2022;13:1089214. doi:10.3389/fphar.2022.1089214

Francque SM, Bedossa P, Ratziu V, et al. A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH. *N Engl J Med*. 2021;385:1547-1558. doi:10.1056/NEJMoa2036205

Frias JP, Nauck MA, Van J, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. *Lancet*. 2018;392:2180-2193. doi:10.1016/S0140-6736(18)32260-8

Geng L, Lam KSL, Xu A. The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. *Nat Rev Endocrinol.* 2020;16:654-667. doi:10.1038/s41574-020-0386-0

Harrison SA, Bashir MR, Guy CD, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet.* 2019;394:2012-2024. doi:10.1016/S0140-6736(19)32517-6

Harrison SA, Thang C, Bolze S, et al. Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: a phase II randomized placebo-controlled trial (DESTINY-1). *J Hepatol.* 2023;78:914-925. doi:10.1016/j.jhep.2023.02.004

Harrison SA, Ratziu V, Anstee QM, et al. Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis. *Aliment Pharmacol Ther.* 2024;59:51-63. doi:10.1111/apt.17734

Harrison S, Bedossa P, Guy CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. *N Engl J Med.* 2024;390:497-509. doi:10.1056/NEJMoa2309000

Karim G, Bansal MB. Resmetirom: an orally administered, smallmolecule, liver-directed, β -selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. *touchREV Endocrinol.* 2023;19:60-70. doi:10.17925/EE.2023.19.1.60

Lee E, Korf H, Vidal-Puig A. An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease. *J Hepatol.* 2023;78:1048-1062. doi:10.1016/j.jhep.2023.01.024

Lefere S, Puengel T, Hundertmark J, et al. Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages^{*}. *J Hepatol.* 2020;73:757-770. doi:10.1016/j.jhep.2020.04.025

Legaki A-I, Moustakas II, Sikorska M, et al. Hepatocyte mitochondrial dynamics and bioenergetics in obesity-related non-alcoholic fatty liver disease. *Curr Obes Rep.* 2022;11:126-143. doi:10.1007/s13679-022-00473-1

Loomba R, Sanyal AJ, Kowdley KV, et al. Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH. *N Engl J Med.* 2023;389:998-1008. doi:10.1056/NEJMoa2304286

Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. *N Engl J Med.* 2021;384:1113-1124. doi:10.1056/NEJMoa2028395

O'Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. *Lancet.* 2018;392:637-649. doi:10.1016/S0140-6736(18)31773-2

Ritter MJ, Amano I, Hollenberg AN. Thyroid hormone signaling and the liver. *Hepatology*. 2020;72:742-752. doi:10.1002/hep.31296

Romero-Gómez M, Lawitz E, Shankar RR, et al. A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease. *J Hepatol*. 2023;79:888-897. doi:10.1016/j.jhep.2023.05.013

Saponaro F, Sestito S, Runfola M, et al. Selective thyroid hormone receptor-beta (TR β) agonists: new perspectives for the treatment of metabolic and neurodegenerative disorders. *Front Med (Lausanne)*. 2020;7:331. doi:10.3389/fmed.2020.00331

Sinha RA, Singh BK, Yen PM. Thyroid hormone regulation of hepatic lipid and carbohydrate metabolism. *Trends Endocrinol Metab*. 2014;25:538-545. doi:10.1016/j.tem.2014.07.001

Sinha RA, Yen PM. Thyroid hormone-mediated autophagy and mitochondrial turnover in NAFLD. *Cell Biosci*. 2016;6:46. doi:10.1186/s13578-016-0113-7

Sinha RA, Singh BK, Yen PM. Direct effects of thyroid hormones on hepatic lipid metabolism. *Nat Rev Endocrinol*. 2018;14:259-269. doi:10.1038/nrendo.2018.10

Taub R, Chiang E, Chabot-Blanchet M, et al. Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor- β agonist. *Atherosclerosis*. 2013;230:373-380. doi:10.1016/j.atherosclerosis.2013.07.056

Rising to the Need to Improve Diagnosis in the Era of Disease-Specific Therapy

Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. *Hepatology*. 2007;45:846-854. doi:10.1002/hep.21496

Anstee QM, Berentzen TL, Nitze LM, et al. Prognostic utility of Fibrosis-4 Index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individuals with obesity and/or type 2 diabetes: a longitudinal cohort study. *Lancet Reg Health Eur*. 2023;36:100780. doi:10.1016/j.lanepe.2023.100780

Boursier J, Tsochatzis EA. Case-finding strategies in non-alcoholic fatty liver disease. *JHEP Rep*. 2020;3:100219. doi:10.1016/j.jhepr.2020.100219

Boyle M, Tiniakos D, Schattenberg JM, et al. Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. *JHEP Rep*. 2019;1:188-198. doi:10.1016/j.jhepr.2019.06.004

Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. *J Hepatol*. 2008;48:835-847. doi:10.1016/j.jhep.2008.02.008

Chalasani N, Younossi Z, Lavine JE. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. *Hepatology*. 2018;67:328-357. doi:10.1002/hep.29367

Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). *Endocr Pract.* 2022;28:528-562. doi:10.1016/j.eprac.2022.03.010

Daniels SJ, Leeming DJ, Eslam M, et al. ADAPT: an algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis. *Hepatology.* 2019;69:1075-1086. doi:10.1002/hep.30163

Day J, Patel P, Parkes J, et al. Derivation and performance of standardized enhanced liver fibrosis (ELF) test thresholds for the detection and prognosis of liver fibrosis. *J Appl Lab Med.* 2019;3:815-826. doi:10.1373/jalm.2018.027359

Eddowes PJ, Sasso M, Allison M, et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. *Gastroenterology.* 2019;156:1717-1730. doi:10.1053/j.gastro.2019.01.042

European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. *J Hepatol.* 2021;75:659-689. doi:10.1016/j.jhep.2021.05.025

Han MAT, Vipani A, Nouredin N, et al. MR elastography-based liver fibrosis correlates with liver events in nonalcoholic fatty liver patients: a multicenter study. *Liver Int.* 2020;40:2242-2251. doi:10.1111/liv.14593

Harrison SA, Bashir MR, Guy CD, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet.* 2019;394:2012-2024. doi:10.1016/S0140-6736(19)32517-6

Harrison SA, Ratziu V, Magnanensi J, et al. NIS2+™, an optimisation of the blood-based biomarker NIS4® technology for the detection of at-risk NASH: a prospective derivation and validation study. *J Hepatol.* 2023;79:758-767. doi:10.1016/j.jhep.2023.04.031

Kanwal F, Shubrook JH, Adams LA, et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. *Gastroenterology.* 2021;161:1657-1669. doi:10.1053/j.gastro.2021.07.049

Loomba R, Wolfson T, Ang B, et al. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. *Hepatology.* 2014;60:1920-1928. doi:10.1002/hep.27362

Loomba R, Sirlin CB, Ang B, et al. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). *Hepatology.* 2015;61:1239-1250. doi:10.1002/hep.27647

Loomba R, Sanyal AJ, Kowdley KV, et al. Factors associated with histologic response in adult patients with nonalcoholic steatohepatitis. *Gastroenterology.* 2019;156:88-95.e5. doi:10.1053/j.gastro.2018.09.021

McPherson S, Stewart SF, Henderson E, et al. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. *Gut*. 2010;59:1265-1269. doi:10.1136/gut.2010.216077

McPherson S, Hardy T, Dufour J-F, et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. *Am J Gastroenterol*. 2017;112:740-751. doi:10.1038/ajg.2016.453

Newsome PN, Sasso M, Deeks JJ, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. *Lancet Gastroenterol Hepatol*. 2020;5:362-373. doi:10.1016/S2468-1253(19)30383-8

Noureddin M, Yates KP, Vaughn IA, et al. Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients. *Hepatology*. 2013;58:1644-1654. doi:10.1002/hep.26465

Noureddin N, Alkhouri N, Brown KA, et al. Driving nonalcoholic steatohepatitis forward using the FibroScan aspartate aminotransferase score, but obey the traffic lights. *Hepatology*. 2020;72:2228-2230. doi:10.1002/hep.31498

Noureddin M, Truong E, Gornbein JA, et al. MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis. *J Hepatol*. 2022;76:781-787. doi:10.1016/j.jhep.2021.11.012

Noureddin M, Truong E, Mayo R, et al. Serum identification of at-risk MASH: the metabolomics-advanced steatohepatitis fibrosis score (MASEF). *Hepatology*. 2024;79:135-148. doi:10.1097/HEP.0000000000000542

Patel J, Bettencourt R, Cui J, et al. Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis. *Therap Adv Gastroenterol*. 2016;9:692-701. doi:10.1177/1756283X16656735

Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. *Hepatology*. 2023;77:1797-1835. doi:10.1097/HEP.0000000000000323

Sanyal AJ, Van Natta ML, Clark J, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. *N Engl J Med*. 2021;385:1559-1569. doi:10.1056/NEJMoa2029349

Selvaraj EA, Mózes FE, Jayaswal ANA, et al. Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis. *J Hepatol*. 2021;75:770-785. doi:10.1016/j.jhep.2021.04.044

Siddiqui MS, Vuppalanchi R, Van Natta ML, et al. Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease. *Clin Gastroenterol Hepatol*. 2019;17:156-163.e2. doi:10.1016/j.cgh.2018.04.043

Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. *Hepatology*. 2006;43:1317-1325. doi:10.1002/hep.21178

Tapper EB, Lok AS-F. Use of liver imaging and biopsy in clinical practice. *N Engl J Med*. 2017;377:756-768. doi:10.1056/NEJMra1610570

Taylor RS, Taylor RJ, Bayliss S, et al. Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis. *Gastroenterology*. 2020;158:1611-1625.e12. doi:10.1053/j.gastro.2020.01.043

Vali Y, Lee J, Boursier J, et al. Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis. *J Hepatol*. 2020;73:252-262. doi:10.1016/j.jhep.2020.03.036

Vali Y, Lee J, Boursier J, et al. Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study. *Lancet Gastroenterol Hepatol*. 2023;8:714-725. doi:10.1016/S2468-1253(23)00017-1

Integrating MASLD-/MASH-Specific Therapy Into Practice

Agency for Healthcare Quality and Research: The SHARE Approach
<https://www.ahrq.gov/health-literacy/professional-training/shared-decision/index.html>

Alkhoury N, Tincopa M, Loomba R, et al. What does the future hold for patients with nonalcoholic steatohepatitis: diagnostic strategies and treatment options in 2021 and beyond? *Hepatol Commun*. 2021;5:1810-1823. doi:10.1002/hep4.1814

Harrison S, Bedossa P, Guy CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. *N Engl J Med*. 2024;390:497-509. doi:10.1056/NEJMoa2309000

Loomba R, Sanyal AJ, Kowdley KV, et al. Factors associated with histologic response in adult patients with nonalcoholic steatohepatitis. *Gastroenterology*. 2019;156:88-95.e5. doi:10.1053/j.gastro.2018.09.021

Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. *N Engl J Med*. 2021;384:1113-1124. doi:10.1056/NEJMoa2028395

Patel J, Bettencourt R, Cui J, et al. Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis. *Therap Adv Gastroenterol*. 2016;9:692-701. doi:10.1177/1756283X16656735

Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. *N Engl J Med*. 2021;384:989-1002. doi:10.1056/NEJMoa2032183

Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. *Gastroenterology*. 2015;149:367-378.e5. doi:10.1053/j.gastro.2015.04.005